Importantly, LSD1-specific inhibitors have recently been developed [28], and in particular, a Phase IIa clinical trial of the novel LSD1 inhibitor Iadademstat (ORY-1001) in combination with Azacitidine has just started for acute myeloid leukemia (AML) (ALICE study); also a Phase IIa clinical trial of Iadademstat in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer (SCLC) (CLEPSIDRA study) has started. This evidence concerns the gene KDM1A and acute myeloid leukemia.